Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02548559 · ClinicalTrials.gov registry record · Phase 2
Sublingual Cannabidiol for Anxiety
A Phase 2 study of Anxiety, sponsored by Staci Gruber, Ph.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02548559: Completed Phase 2 study of Anxiety, sponsored by Staci Gruber, Ph.D..
NCT02548559 is a Phase 2 study of Anxiety that has completed, run by Staci Gruber, Ph.D.. The registered enrollment target is 31 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02548559, a Phase 2 study of Anxiety, has completed, sponsored by Staci Gruber, Ph.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.
Primary Outcome
The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3, with total scores ranging from 0 to 63 (higher scores indicating more anxiety).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Full-Spectrum Cannabidiol
- DRUG Single-Compound Cannabidiol
Study Locations (1)
Massachusetts
- McLean Hospital Brain Imaging Center - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 2 |
What the finished NCT02548559 record still lists
NCT02548559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02548559 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02548559 about?
NCT02548559 is a clinical study titled "Sublingual Cannabidiol for Anxiety". This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment ...
What is the current status of trial NCT02548559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-08-14. Estimated completion is 2025-03-13.
What conditions does trial NCT02548559 study?
This clinical trial studies the following conditions: Anxiety.
What interventions are being tested in trial NCT02548559?
The interventions under investigation include: Placebo (DRUG), Full-Spectrum Cannabidiol (DRUG), Single-Compound Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT02548559?
This trial is sponsored by Staci Gruber, Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02548559 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02548559's enrollment target sits among peer trials
31 299th of 364 higher than 66 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Use of CBD in the Treatment of Anxiety
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI